Mga Batayang Estadistika
| LEI | 529900NDQQGU5H4UJK81 |
| CIK | 1098972 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Agenus Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 12, 2025 |
As filed with the Securities and Exchange Commission on August 11, 2025 S-8 As filed with the Securities and Exchange Commission on August 11, 2025 Registration No. |
|
| August 12, 2025 |
Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 AGENUS INC Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common stock, $0. |
|
| August 11, 2025 |
Exhibit 10.3 Certain portions of this exhibit (indicated by “[***]”) have been omitted in compliance with Regulation S-K Item 601(b)(10)(iv) as the Company determined the omitted information (i) is not material and (ii) is the type that the Company customarily and actually treats as private or confidential. AGENUS INC. SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreeme |
|
| August 11, 2025 |
Exhibit 10.2 Certain portions of this exhibit (indicated by “[***]”) have been omitted in compliance with Regulation S-K Item 601(b)(10)(iv) as the Company determined the omitted information (i) is not material and (ii) is the type that the Company customarily and actually treats as private or confidential. AGENUS ZYDUS BOT/BAL LICENSE AGREEMENT This License Agreement (this Agreement ) dated as of |
|
| August 11, 2025 |
Exhibit 99.1 Agenus Announces Second Quarter 2025 Financial Results and Virtual Meeting to Discuss Strategic Progress • Zydus Lifesciences collaboration to close in Q3 with $91M capital infusion to support clinical and regulatory milestones • BOT/BAL delivers 42% two-year survival in refractory MSS CRC and consistent activity across multiple solid cancers, to be presented at an oral session at ESM |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29089 Agenus Inc. (exact na |
|
| August 11, 2025 |
Exhibit 10.1 Certain portions of this exhibit (indicated by “[***]”) have been omitted in compliance with Regulation S-K Item 601(b)(10)(iv) as the Company determined the omitted information (i) is not material and (ii) is the type that the Company customarily and actually treats as private or confidential. ASSET PURCHASE AGREEMENT This ASSET PURCHASE AGREEMENT (this “Agreement”) is dated June 3, |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2025 AGENUS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-29089 06-1562417 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| June 20, 2025 |
FORM 8-K Item 5.07 Submission of Matters to a Vote of Security Holders. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2025 AGENUS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-29089 06-1562417 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| June 6, 2025 |
DEFR14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 2) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2) |
|
| June 4, 2025 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus’ Biologics Manufacturing in the US • $75M upfront payment to Agenus for the transfer of manufacturing assets • $50M of contingent payments to Agenus • Exclusive license for BOT/BAL in India and Sri Lanka • $16M equity investment at $7.50 per share LEXINGTON, Mass– J |
|
| June 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 03, 2025 AGENUS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-29089 06-1562417 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 28, 2025 |
AGENUS INC. 3 Forbes Road Lexington, MA 02421 CORRESP AGENUS INC. 3 Forbes Road Lexington, MA 02421 May 28, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.W. Washington, D.C. 20549 Attention: Joshua Gorsky Re: Agenus Inc. Registration Statement on Form S-3 (File No. 333-287197) Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1 |
|
| May 12, 2025 |
Exhibit 99.1 Agenus Reports Q1 2025 Financial Results and Key Business Updates • BOT/BAL Achieves Breakthrough Response Rates in MSS Cancers — Oral AACR Data Spotlight Pan-Tumor Neoadjuvant Success • Seasoned Leader Onboard to Accelerate BOT/BAL Toward Registration Milestones • Near-Term Capital Transaction Poised to Bolster Liquidity May 12, 2025 LEXINGTON, Mass.-(BUSINESS WIRE)- Agenus Inc. (“Ag |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29089 Agenus Inc. (exact n |
|
| May 12, 2025 |
As filed with the Securities and Exchange Commission on May 12, 2025 Table of Contents As filed with the Securities and Exchange Commission on May 12, 2025 Registration No. |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 AGENUS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-29089 06-1562417 (State or Other Jurisdiction of Incorporation) (Commission File Number) ( |
|
| May 12, 2025 |
Calculation of Registration Fee Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Agenus Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration of Fee Fee |
|
| May 5, 2025 |
DEFR14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2) |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| March 17, 2025 |
Exhibit 4.14 AMENDMENT TO NOTES, AMENDMENT of WARRANTS And Sale of New Warrants This Amendment to Notes, Amendment of Warrants and Sale of New Warrants (this “Amendment”) effective as of February 20, 2025 by and between (a) Agenus Inc., a Delaware corporation, having an address at 3 Forbes Road, Lexington, MA 02421 (the “Borrower”), and (b) Mark Berg and Nicole Berg, Alice Saraydarian, Khalil Barr |
|
| March 17, 2025 |
Insider Trading Policy. Filed herewith. Exhibit 19.1 AGENUS INC. Securities Trading Policy This Securities Trading Policy (this “Policy”) describes the requirements that Agenus Inc. and its subsidiaries (with the exception of MiNK Therapeutics, Inc.1) (collectively, the “Company” or “Agenus”) have adopted regarding the trading, and causing the trading of, the Company's securities. I. PURPOSE Agenus is committed to complying with all rel |
|
| March 17, 2025 |
Subsidiaries of Agenus Inc. Filed herewith. EXHIBIT 21.1 SUBSIDIARIES OF AGENUS INC. Antigenics LLC., a Delaware limited liability company and a wholly-owned subsidiary of Agenus Inc. Agenus Holdings 2024, LLC, a Delaware limited liability company and a wholly-owned subsidiary of Agenus Inc. Agenus Royalty Fund, LLC, a Delaware limited liability company and a wholly-owned subsidiary of Agenus Inc. Agenus West, LLC, a Delaware limited liabil |
|
| March 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29089 Agenus Inc. (exact name o |
|
| March 11, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2025 AGENUS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-29089 06-1562417 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| March 11, 2025 |
Exhibit 99.1 Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program LEXINGTON, Mass.-(BUSINESS WIRE)- Agenus Inc. (“Agenus” or the “Company”) (Nasdaq: AGEN), an immuno-oncology company advancing innovative cancer therapies, today reported financial and operational results for Q4 and full-ye |
|
| February 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2025 AGENUS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-29089 06-1562417 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| February 26, 2025 |
Exhibit 4.1 Form of AMENDED AND RESTATED 2022 A WARRANT (SUPERSEDING IN ITS ENTIRETY ORIGINAL 2022 A WARRANT ISSUED NOVEMBER [ ], 2020) THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTH |
|
| February 26, 2025 |
Exhibit 4.2 Form of AMENDED AND RESTATED 2022 b WARRANT (SUPERSEDING IN ITS ENTIRETY ORIGINAL 2022 b WARRANT ISSUED NOVEMBER [ ], 2020) THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTH |
|
| February 26, 2025 |
Exhibit 4.3 Form of 2025 C WARRANT THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED OR ASSIGNED UNLESS (I) A REGISTRATION STATEMENT COVERING SUCH SHARES |
|
| February 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 04, 2025 AGENUS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-29089 06-1562417 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| December 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 05, 2024 AGENUS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-29089 06-1562417 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| December 5, 2024 |
Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs Exhibit 99.1 Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs LEXINGTON, Mass. – December 5, 2024 – Agenus Inc., a leader in immuno-oncology, today announced further details of its strategic realignment aimed at streamlining operations, strengthening its financial position, and prioritizing the advancement of its most impactful programs as it prepares |
|
| November 27, 2024 |
Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment Exhibit 99.1 Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment LEXINGTON, Mass.-(BUSINESS WIRE) - Agenus Inc. (“Agenus” or the “Company”) (Nasdaq: AGEN), an immuno-oncology company focused on innovation has successfully secured a $22 million non-amortizing mortgage backed by its Berkeley-based Biologics CMC facility ("901 Heinz") and its 66-acre biomanufacturing-z |
|
| November 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 26, 2024 AGENUS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-29089 06-1562417 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| November 14, 2024 |
AGEN / Agenus Inc. / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| November 14, 2024 |
AGEN / Agenus Inc. / Point72 Asset Management, L.P. - AGENUS INC. Passive Investment SC 13G/A 1 p24-3352sc13ga.htm AGENUS INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Agenus Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 00847G804 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate bo |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29089 Agenus Inc. (exa |
|
| November 12, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 AGENUS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-29089 06-1562417 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| November 12, 2024 |
Exhibit 99.1 Agenus Reports Third Quarter 2024 Financial Results and Strategic Advancements in BOT/BAL Development Transforming Cancer Treatment with BOT/BAL While Strengthening Financial Foundations LEXINGTON, Mass.-(BUSINESS WIRE) - Agenus Inc. (“Agenus” or the “Company”) (Nasdaq: AGEN), an immuno-oncology company focused on innovation, today provided a corporate update and reported financial re |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 08, 2024 AGENUS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-29089 06-1562417 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| November 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2024 AGENUS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-29089 06-1562417 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| August 8, 2024 |
Agenus Reports Second Quarter 2024 Operational and Financial Results EX-99.1 3 d800799dex991.htm EX-99.1 Exhibit 99.1 Agenus Reports Second Quarter 2024 Operational and Financial Results • Robust Phase 2 Data Validate Consistent Clinical Activity of BOT/BAL in Metastatic MSS CRC • Maturing Data Across BOT/BAL Program Demonstrate Broad Solid Tumor Activity in the Late Stage, First-Line with Chemo Combinations, and Neoadjuvant disease • Commenced Interactions with Gl |
|
| August 8, 2024 |
Agenus Inc. Up to 13,843,015 Shares Common Stock Table of Contents As Filed Pursuant to 424(b)(5) Registration No. 333-272911 PROSPECTUS SUPPLEMENT (To Prospectus dated March 18, 2024) Agenus Inc. Up to 13,843,015 Shares Common Stock We have renewed our “at the market” (“ATM”) facility with B. Riley Securities, Inc. (formerly B. Riley FBR, Inc., “B. Riley”) under our At Market Issuance Sales Agreement (“ATM Sales Agreement”) dated July 22, 2020, |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29089 Agenus Inc. (exact na |
|
| August 8, 2024 |
EX-99.2 4 d800799dex992.htm EX-99.2 Exhibit 99.2 Agenus Announces Appointment of Tom Harrison to Board of Directors Advertising Veteran Tapped to Elevate Awareness of Agenus and Its Innovative Pipeline Lexington, MA – Agenus Inc. (NASDAQ: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced the appointment of Tom Harrison to its Board o |
|
| August 8, 2024 |
Exhibit 10.1 Execution Version PURCHASE AND SALE AGREEMENT dated as of May 6, 2024 by and among AGENUS INC., AGENUS ROYALTY FUND, LLC, AGENUS HOLDINGS 2024, LLC and LIGAND PHARMACEUTICALS INCORPORATED SPECIFIC TERMS IN THIS AGREEMENT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED. THESE REDACTED TERMS HAVE BEEN MARKED IN THIS AGREEMENT WITH THREE ASTERISKS [** |
|
| August 8, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 AGENUS INC. (Exact name of registrant as specified in its charter) Delaware 000-29089 06-1562417 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| August 2, 2024 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2024 AGENUS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-29089 06-1562417 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| June 25, 2024 |
As filed with the Securities and Exchange Commission on June 25, 2024 As filed with the Securities and Exchange Commission on June 25, 2024 Registration No. |
|
| June 25, 2024 |
Filing Fee Table. Filed Herewith Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Agenus Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, $0.01 par value per s |
|
| June 17, 2024 |
Strategic leadership to drive next phase of growth for the company Agenus Announces Appointment of Dr. Jennifer Buell to Its Board of Directors 6/17/2024 Strategic leadership to drive next phase of growth for the company LEXINGTON, Mass.-(BUSINESS WIRE)- Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, is pleased to announce the appointment of Dr. Jennifer Buell to its Board of Directors, on June 1 |
|
| June 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2024 AGENUS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-29089 06-1562417 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| June 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2024 AGENUS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-29089 06-1562417 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| June 10, 2024 |
AGEN / Agenus Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Agenus Inc Title of Class of Securities: Common Stock CUSIP Number: 00847G804 Date of Event Which Requires Filing of this Statement: May 31, 2024 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) |
|
| May 30, 2024 |
Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2024 AGENUS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-29089 06-1562417 (State or Other Jurisdiction of Incorporation) (Commission File Number) ( |
|
| May 7, 2024 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement Capital infusion will support botensilimab and balstilimab (BOT/BAL) clinical development, confirmatory Phase 3 trial, and launch readiness activities Ligand entitled to royalties and milestone payments on six Agenus-partnered programs as well as royalties on future global net sales generated b |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29089 Agenus Inc. (exact n |
|
| May 7, 2024 |
Exhibit 99.1 Agenus Reports First Quarter 2024 Results $100M royalty financing agreement with Ligand announced, bringing in capital via non-equity means to support critical botensilimab/balstilimab (BOT/BAL) development and launch readiness activities Company has reestablished its market compliance with Nasdaq Listing Notable clinical results observed in Phase 1 and Phase 2 studies of BOT/BAL in m |
|
| May 7, 2024 |
DB1/ 147056721.4 Exhibit 4.1 Form of 2024 A WARRANT THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED OR ASSIGNED UNLESS (I) A REGISTRATION STATEMENT COVE |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 06, 2024 AGENUS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-29089 06-1562417 (State or Other Jurisdiction of Incorporation) (Commission File Number) ( |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 07, 2024 AGENUS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-29089 06-1562417 (State or Other Jurisdiction of Incorporation) (Commission File Number) ( |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 5, 2024 |
Exhibit 3.1 CERTIFICATE OF EIGHTH AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION AGENUS INC., a corporation organized and existing under the laws of the State of Delaware, hereby certifies as follows: 1. The name of the corporation is Agenus Inc. (the “Corporation”). The Corporation’s original Certificate of Incorporation was filed with the Secretary of State of the State of De |
|
| April 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 3, 2024 AGENUS INC. (Exact name of registrant as specified in charter) Delaware 000-29089 06-1562417 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R |
|
| March 15, 2024 |
S-8 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Agenus Inc. (Exact name of registrant as specified in its charter) Delaware 06-1562417 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 3 Forbes Road, Lexington, MA 02421 (Address of principal executive offic |
|
| March 15, 2024 |
Amendment to the Agenus Inc. 2015 Inducement Equity Plan. Filed herewith. EX-99.2 Exhibit 99.2 AMENDMENT TO 2015 INDUCEMENT EQUITY PLAN The 2015 Inducement Equity Plan of Agenus Inc. (the “Plan”) be and hereby is amended as follows: 1. Section 3(a) of the Plan is hereby deleted in its entirety and replaced with the following: (a) Number of Shares. Subject to adjustment under Section 3(b), the aggregate number of shares of Common Stock of the Company (the “Common Stock”) |
|
| March 15, 2024 |
Filing Fee Table. Filed herewith. EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Agenus Inc. |
|
| March 14, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2024 AGENUS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-29089 06-1562417 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| March 14, 2024 |
Power of Attorney (included in the signature page to this Registration Statement). Table of Contents As filed with the Securities and Exchange Commission on March 14, 2024 Registration No. |
|
| March 14, 2024 |
Agenus Reports Fourth Quarter and Full Year 2023 Results FDA Grants Fast Track designation for BOT/BAL in metastatic, refractory colorectal cancer (CRC) patients who have failed 1st and 2nd line standard of care treatments Data from Phase 1 of BOT/BAL in refractory CRC showed durable ORR of 24% in patients with non-active liver metastases (NLM); Completed enrollment of randomized Phase 2 trial (n=230) Clinical data sets path for expansion opportunities in pancreas, lung, neoadjuvant CRC, and melanoma LEXINGTON, Mass. |
|
| March 14, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Agenus Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(3) Fee Rate Amount of Registration Fee Fees to |
|
| March 14, 2024 |
As filed with the Securities and Exchange Commission on March 14, 2024 Table of Contents As filed with the Securities and Exchange Commission on March 14, 2024 Registration No. |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29089 Agenus Inc. (exact name o |
|
| March 14, 2024 |
Exhibit 97.1 AGENUS INC. POLICY FOR RECOUPMENT OF EXECUTIVE INCENTIVE COMPENSATION IN THE EVENT OF ACCOUNTING RESTATEMENT 1. Introduction The Board of Directors (the “Board”) of Agenus Inc. (the “Company”) has adopted this policy (the “Policy”) providing for the Company’s recoupment of certain incentive-based compensation received by Covered Executives (as defined below) in the event that the Comp |
|
| March 14, 2024 |
Exhibit 10.9.1 AMENDMENT NO. 4 TO CONSULTING AGREEMENT This AMENDMENT NO. 4 TO CONSULTING AGREEMENT (this “Amendment 4”) is entered into as of December 31, 2023 (hereinafter the “Amendment 4 Effective Date”), by and between Agenus Inc., a Delaware corporation having an address at 3 Forbes Road, Lexington, MA 02421, USA (the “Company”), and Brian Corvese (the “Consultant”) (each a “Party” and toget |
|
| March 14, 2024 |
Subsidiaries of Agenus Inc. Filed herewith. EXHIBIT 21.1 SUBSIDIARIES OF AGENUS INC. Antigenics LLC., a Delaware limited liability company and a wholly-owned subsidiary of Agenus Inc. Agenus Royalty Fund, LLC, a Delaware limited liability company and a wholly-owned subsidiary of Agenus Inc. Agenus West, LLC, a Delaware limited liability company and a wholly-owned subsidiary of Agenus Inc. Agenus UK Limited, a private limited company organiz |
|
| February 29, 2024 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2) |
|
| February 26, 2024 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 21, 2024 |
AGEN / Agenus Inc. / Point72 Asset Management, L.P. - AGENUS INC Passive Investment SC 13G 1 p24-0956sc13g.htm AGENUS INC SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Agenus Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 00847G705 (CUSIP Number) February 20, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des |
|
| February 21, 2024 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) EX-99.1 2 p24-0956exhibit99.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing a |
|
| February 15, 2024 |
PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 15, 2024 |
Exhibit 99.1 February 15, 2024 To Our Valued Shareholders, Agenus is committed to enhancing shareholder value and securing the long-term success of our company. In response to the current market price of our shares and to facilitate our continued compliance with the Nasdaq listing standards, we are proposing a reverse stock split at a ratio of 1-for-20. Reverse Stock Split Rationale The proposed r |
|
| February 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2024 AGENUS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-29089 06-1562417 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| February 14, 2024 |
AGEN / Agenus Inc. / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 13, 2024 |
AGEN / Agenus Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Agenus Inc Title of Class of Securities: Common Stock CUSIP Number: 00847G705 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d |
|
| February 9, 2024 |
AGEN / Agenus Inc. / Artal International S.C.A. - SC 13G/A Passive Investment SC 13G/A 1 d686535dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 1) Agenus Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 00847G705 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the approp |
|
| January 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2024 AGENUS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-29089 06-1562417 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| December 8, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 04, 2023 AGENUS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-29089 06-1562417 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29089 Agenus Inc. (exa |
|
| November 7, 2023 |
Agenus Reports Third Quarter 2023 Results Exhibit 99.1 Agenus Reports Third Quarter 2023 Results Conference Call on Tuesday, November 7, 2023, at 9:00 a.m. ET LEXINGTON, Mass.-(BUSINESS WIRE)-November 7, 2023-Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced results for the third quarter 2023. Agenus executives will host a conference call and |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 7, 2023 Date of Report (Date of earliest event reported) AGENUS INC. (Exact name of registrant as specified in its charter) DELAWARE 000-29089 06-1562417 (State or other jurisdiction (Commission (IRS Employer of incorporatio |
|
| August 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2023 AGENUS INC. (Exact name of registrant as specified in its charter) DELAWARE 000-29089 06-1562417 (State or other jurisdiction (Commission (IRS Employer of incorporatio |
|
| August 23, 2023 |
Exhibit 99.1 Agenus Prioritizes Resources to Accelerate Registration and Commercialization of BOT/BAL Program in Multiple Cancers Strategic Prioritization to Deliver Savings of $40M Through End of 2023 LEXINGTON, Mass.-(BUSINESS WIRE)-August 23, 2023-Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a pioneer in immuno-oncology, today announced a strategic initiative to prioritize and focus resources to acce |
|
| August 8, 2023 |
Agenus Reports Second Quarter 2023 Results Exhibit 99.1 Agenus Reports Second Quarter 2023 Results LEXINGTON, Mass.-(BUSINESS WIRE)-August 8, 2023-Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced results for the second quarter 2023. Key accomplishments and highlights include: Botensilimab Update: Botensilimab/balstilimab combination data presented at ESMO-GI |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 AGENUS INC. (Exact name of registrant as specified in its charter) DELAWARE 000-29089 06-1562417 (State or other jurisdiction (Commission (IRS Employer of incorporation |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29089 Agenus Inc. (exact na |
|
| June 23, 2023 |
As filed with the Securities and Exchange Commission on June 23, 2023 S-3ASR Table of Contents As filed with the Securities and Exchange Commission on June 23, 2023 Registration No. |
|
| June 23, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-3ASR (Form Type) Agenus Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1)(2) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration of Fee |
|
| June 23, 2023 |
Exhibit 4.1 AGENUS INC. and [ ], as Trustee INDENTURE Dated as of [ ], [ ] TABLE OF CONTENTS ARTICLE 1. DEFINITIONS AND INCORPORATION BY REFERENCE 6 1.1. DEFINITIONS. 6 1.2. OTHER DEFINITIONS. 10 1.3. INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT. 12 1.4. RULES OF CONSTRUCTION. 12 ARTICLE 2. THE SECURITIES 12 2.1. ISSUABLE IN SERIES. 12 2.2. ESTABLISHMENT OF TERMS OF SERIES OF SECURITIES. 13 2 |
|
| June 23, 2023 |
Filing Fee Table. Filed herewith. EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Agenus Inc. |
|
| June 23, 2023 |
S-8 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Agenus Inc. (Exact name of registrant as specified in its charter) Delaware 06-1562417 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 3 Forbes Road, Lexington, MA 02421 (Address of principal executive offic |
|
| June 15, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2023 AGENUS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-29089 06-1562417 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 26, 2023 |
INKT / MiNK Therapeutics Inc / AGENUS INC - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* MINK THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 603693102 (CUSIP Number) Garo H. Armen, Ph.D. Chairman and CEO Agenus Inc. 3 Forbes Road Lexington, MA 02421 (781) 674-4400 (Name, Address and Telephone Number |
|
| May 9, 2023 |
Agenus Provides Corporate Update and First Quarter 2023 Financial Results Exhibit 99.1 Agenus Provides Corporate Update and First Quarter 2023 Financial Results At a late-breaking presentation at ASCO-GI, botensilimab/balstilimab combination demonstrated a 63% 12-month overall survival rate in metastatic colorectal cancer patients who have failed a median of four prior treatments, more than double the survival rate reported for available treatments Botensilimab/balstili |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29089 Agenus Inc. (exact n |
|
| May 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 AGENUS INC. (Exact name of registrant as specified in its charter) DELAWARE 000-29089 06-1562417 (State or other jurisdiction (Commission (IRS Employer of incorporation) F |
|
| May 3, 2023 |
INKT / MiNK Therapeutics Inc / AGENUS INC - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* MINK THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 603693102 (CUSIP Number) Garo H. Armen, Ph.D. Chairman and CEO Agenus Inc. 3 Forbes Road Lexington, MA 02421 (781) 674-4400 (Name, Address and Telephone Number |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2023 AGENUS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-29089 06-1562417 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| March 30, 2023 |
Agenus Announces Dividend of 5 Million Shares of MiNK Therapeutics EX-99.1 Exhibit 99.1 Agenus Announces Dividend of 5 Million Shares of MiNK Therapeutics LEXINGTON, Mass., March 30, 2023 (GLOBAL NEWSWIRE) – Agenus Inc. (Nasdaq: AGEN), an immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, today announced that its Board of Directors has declared a dividend of 5 million shares of common stock of its subsidiary, |
|
| March 30, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2023 AGENUS INC. (Exact name of registrant as specified in its charter) DELAWARE 000-29089 06-1562417 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| March 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29089 Agenus Inc. (exact name o |
|
| March 16, 2023 |
Subsidiaries of Agenus Inc. Filed herewith. EXHIBIT 21.1 SUBSIDIARIES OF AGENUS INC. Antigenics LLC., a Delaware limited liability company and a wholly-owned subsidiary of Agenus Inc. Agenus Royalty Fund, LLC, a Delaware limited liability company and a wholly-owned subsidiary of Agenus Inc. Agenus Switzerland Inc., a joint stock company organized under the laws of Switzerland formerly known as 4-Antibody AG, and a wholly-owned subsidiary of |
|
| March 16, 2023 |
Exhibit 4.9 AMENDMENT TO NOTES, Termination of WARRANTS And Sale of New Warrants This Amendment to Notes, Termination of Warrants and Sale of New Warrants (this “Amendment”) is entered into this 30th day of November 2022 by and between (a) Agenus Inc., a Delaware corporation, having an address at 3 Forbes Road, Lexington, MA 02421 (the “Borrower”), and (b) Mark Berg and Nicole Berg, Nicky V LLC an |
|
| March 14, 2023 |
Agenus Reports Fourth Quarter and Full Year 2022 Financial Results and Outlines 2023 Objectives EXHIBIT 99.1 Agenus Reports Fourth Quarter and Full Year 2022 Financial Results and Outlines 2023 Objectives Botensilimab plus balstilimab showed overall response rates of 23% in microsatellite stable colorectal cancer (MSS CRC), 50% in PD-(L)1 refractory non-small cell lung cancer (NSCLC) and in seven additional metastatic, late-line cancers in a total of more than 300 patients Randomized Phase 2 |
|
| March 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 14, 2023 Date of Report (Date of earliest event reported) AGENUS INC. (Exact name of registrant as specified in its charter) Delaware 000-29089 06-1562417 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| February 14, 2023 |
AGEN / Agenus Inc / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 9, 2023 |
AGEN / Agenus Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Agenus Inc. Title of Class of Securities: Common Stock CUSIP Number: 00847G705 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13 |
|
| February 1, 2023 |
EX-99.1 EXHIBIT 1 JOINT FILING AGREEMENT The undersigned agree that the statement on Schedule 13G with respect to the Common Stock, $0.01 par value per share, of Agenus Inc. is, and any amendments thereto signed by each of the undersigned shall be, filed on behalf of each of them pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amende |
|
| February 1, 2023 |
AGEN / Agenus Inc / Artal International S.C.A. - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. ) Agenus Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 00847G705 (CUSIP Number) January 23, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| December 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2022 AGENUS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-29089 06-1562417 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| December 23, 2022 |
Exhibit 4.4 AMENDMENT TO NOTES, TERMINATION OF WARRANTS AND SALE OF NEW WARRANTS This Amendment to Notes, Termination of Warrants and Sale of New Warrants (this ?Amendment?) is entered into this 30th day of November 2022 by and between (a) Agenus Inc., a Delaware corporation, having an address at 3 Forbes Road, Lexington, MA 02421 (the ?Borrower?), and (b) Mark Berg and Nicole Berg, Nicky V LLC an |
|
| December 23, 2022 |
As filed with the Securities and Exchange Commission on December 23, 2022 S-3ASR Table of Contents As filed with the Securities and Exchange Commission on December 23, 2022 Registration No. |
|
| December 23, 2022 |
Calculation of Registration Fee Exhibit 107 Calculation of Filing Fee Table Form S-3ASR (Form Type) Agenus Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration of Fee |
|
| December 2, 2022 |
Exhibit 4.2 Form of 2022 B WARRANT THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED OR ASSIGNED UNLESS (I) A REGISTRATION STATEMENT COVERING SUCH SHARES |
|
| December 2, 2022 |
Exhibit 4.1 Form of 2022 A WARRANT THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED OR ASSIGNED UNLESS (I) A REGISTRATION STATEMENT COVERING SUCH SHARES |
|
| December 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2022 Agenus inc. (Exact name of registrant as specified in its charter) Delaware 000-29089 06-1562417 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 8, 2022 Date of Report (Date of earliest event reported) AGENUS INC. (Exact name of registrant as specified in its charter) Delaware 000-29089 06-1562417 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29089 Agenus Inc. (exa |
|
| November 8, 2022 |
Agenus Provides Corporate Update and Third Quarter 2022 Financial Report EXHIBIT 99.1 Agenus Provides Corporate Update and Third Quarter 2022 Financial Report Company to present expanded data from Phase 1 study of botensilimab (Fc-enhanced anti-CTLA-4) at plenary session of the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting Initiated Phase 2 ACTIVATE trials of botensilimab in advanced MSS colorectal cancer and advanced melanoma R&D Event (“The Road Take |
|
| August 11, 2022 |
As filed with the Securities and Exchange Commission on August 11, 2022 As filed with the Securities and Exchange Commission on August 11, 2022 Registration No. |
|
| August 11, 2022 |
Filing Fee Table. Filed Herewith Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Agenus Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, $0.01 par value per s |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29089 Agenus Inc. (exact na |
|
| August 9, 2022 |
Agenus Provides Corporate Update and Second Quarter 2022 Financial Report EXHIBIT 99.1 Agenus Provides Corporate Update and Second Quarter 2022 Financial Report Botensilimab (Fc-enhanced CTLA-4)/balstilimab (PD-1) combination data presented at the 2022 ESMO World GI Congress demonstrated remarkable clinical activity in microsatellite stable colorectal cancer (MSS CRC) Agenus expects to present additional botensilimab expansion cohort data at upcoming conferences in 2022 |
|
| August 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 9, 2022 Date of Report (Date of earliest event reported) AGENUS INC. (Exact name of registrant as specified in its charter) Delaware 000-29089 06-1562417 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| August 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 AGENUS INC. (Exact name of registrant as specified in its charter) Delaware 000-29089 06-1562417 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| August 5, 2022 |
EXHIBIT 3.1 AGENUS INC. CERTIFICATE OF SEVENTH AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION AGENUS INC., a corporation organized and existing under the laws of the State of Delaware, hereby certifies as follows: 1. The name of the corporation is Agenus Inc. (the ?Corporation?). The Corporation?s original Certificate of Incorporation was filed with the Secretary of State of th |
|
| June 22, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ? Defi |
|
| June 14, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2022 AGENUS INC. (Exact name of registrant as specified in its charter) Delaware 000-29089 06-1562417 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| June 9, 2022 |
PRE 14A 1 d357410dpre14a.htm PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as |
|
| May 10, 2022 |
Agenus Corporate Update and First Quarter 2022 Financial Report EXHIBIT 99.1 Agenus Corporate Update and First Quarter 2022 Financial Report Botensilimab data to be presented and Phase 2 trials to launch. AGEN1571 (ILT2) clinical trials to commence and data presented at AACR. AGEN2373 progressing in the clinic and Gilead milestone payment received. LEXINGTON, Mass., May 10, 2022 (GLOBE NEWSWIRE) - Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an |
|
| May 10, 2022 |
Consulting Agreement dated January 1, 2022 between Agenus Inc. and Jennifer Buell. Filed herewith. Exhibit 10.2 CONSULTING AGREEMENT This Consulting Agreement (the ?Agreement?), effective as of January 01, 2022 (the ?Effective Date?) is made between Agenus Inc., a Delaware corporation, having an address at 3 Forbes Road, Lexington, MA 02421 (?Agenus?), and Jennifer S. Buell, PhD an individual having an address at 88 Pine Street Dover, MA 02030 (the ?Consultant?) (each a ?Party? and collectively |
|
| May 10, 2022 |
Exhibit 10.1 Executive Employment AGREEMENT THIS Executive Employment AGREEMENT (this ?Agreement?) is made and entered into on October 27, 2020 in Lexington, MA, by and between Agenus Inc., a Delaware corporation with a principal place of business at 3 Forbes Rd. Lexington, MA 02421 (the ?Company?), and Steven O?Day (the ?Executive?), effective as of the Executive?s first day of employment with th |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29089 Agenus Inc. (exact n |
|
| May 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 10, 2022 Date of Report (Date of earliest event reported) AGENUS INC. (Exact name of registrant as specified in its charter) Delaware 000-29089 06-1562417 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I |
|
| April 29, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi |
|
| April 8, 2022 |
AGEN / Agenus Inc / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| March 25, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2022 AGENUS INC. (Exact name of registrant as specified in its charter) Delaware 000-29089 06-1562417 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| March 25, 2022 |
Exhibit 3.1 SIXTH AMENDED AND RESTATED BY-LAWS OF AGENUS INC. Adopted by the Incorporator on November 10, 1999 Amended by the Board of Directors on March 14, 2002, on December 17, 2007, on September 11, 2008, on September 16, 2010, January 6, 2011, and on March 23, 2022 ARTICLE I STOCKHOLDERS SECTION 1. PLACE OF MEETINGS. All meetings of stockholders shall be held at the principal office of the co |
|
| March 1, 2022 |
Exhibit 10.12.1Ex AMENDMENT NO. 3 TO CONSULTING AGREEMENT This AMENDMENT NO. 3 TO CONSULTING AGREEMENT (this ?Amendment?) is entered into as of January 31, 2022 (the ?Amendment Effective Date?), by and between Agenus Inc., a Delaware corporation having an address at 3 Forbes Road, Lexington, MA 02421 (?Agenus?), and Evan D. Kearns, an individual with an address at 40 Edgewater Lane, Needham, MA 02 |
|
| March 1, 2022 |
Subsidiaries of Agenus Inc. Filed herewith. EXHIBIT 21.1 SUBSIDIARIES OF AGENUS INC. Antigenics LLC., a Delaware limited liability company and a wholly-owned subsidiary of Agenus Inc. Agenus Royalty Fund, LLC, a Delaware limited liability company and a wholly-owned subsidiary of Agenus Inc. Agenus Switzerland Inc., a joint stock company organized under the laws of Switzerland formerly known as 4-Antibody AG, and a wholly-owned subsidiary of |
|
| March 1, 2022 |
Amendment to the Agenus Inc. 2019 Equity Incentive Plan, dated February 2, 2022. Filed herewith. Exhibit 10.10.2 FIRST AMENDMENT TO THE AGENUS INC. 2019 EQUITY INCENTIVE PLAN This First Amendment (this ?Amendment?) to the Agenus Inc. Incentive Award Plan (as amended to date, the ?Plan?), dated as of February 2, 2022, is made and adopted by Agenus Inc. (the ?Company?), a Delaware corporation. Defined terms used herein without definition shall have the meanings given to such terms in the Plan. |
|
| March 1, 2022 |
Agenus Inc. Up to 100,000,000 Shares Common Stock Table of Contents As Filed Pursuant to 424(b)(5) Registration No. 333-240006 PROSPECTUS SUPPLEMENT (To Prospectus Dated July 22, 2020) Agenus Inc. Up to 100,000,000 Shares Common Stock We have renewed our ?at the market? (?ATM?) facility with B. Riley Securities, Inc. (formerly B. Riley FBR, Inc., ?B. Riley?) under our At Market Issuance Sales Agreement (?ATM Sales Agreement?) dated July 22, 2020, |
|
| March 1, 2022 |
Exhibit 10.11.1 AMENDMENT NO. 2 TO CONSULTING AGREEMENT This AMENDMENT NO. 1 TO CONSULTING AGREEMENT (this ?Amendment 2?) is entered into as of January 1, 2022 (hereinafter the ?Amendment 2 Effective Date?), by and between Agenus Inc., a Delaware corporation having an address at 3 Forbes Road, Lexington, MA 02421, USA (the ?Company?), and Brian Corvese (the ?Consultant?) (each a ?Party? and togeth |
|
| March 1, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2022 AGENUS INC. (Exact name of registrant as specified in its charter) Delaware 000-29089 06-1562417 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| March 1, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Agenus Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Fo |
|
| March 1, 2022 |
Consulting Agreement dated April 30, 2021 between Agenus Inc. and Evan Kearns. Filed herewith. Exhibit 10.12 CONSULTING AGREEMENT This Consulting Agreement (this ?Agreement?), effective as of April 30, 2021 (the ?Effective Date?), is made by and between Agenus Inc., a Delaware corporation having an address at 3 Forbes Road, Lexington, MA 02421 (?Agenus?), and Evan D. Kearns, an individual having an address at 71 Emerson Road, Needham, MA 02492 (the ?Consultant?) (each a ?Party? and collecti |
|
| March 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29089 Agenus Inc. (exact name o |
|
| March 1, 2022 |
Exhibit 99.1 Agenus Corporate Update and Fourth Quarter & Full Year 2021 Financial Report ? Botensilimab (Fc-enhanced) is the first anti-CTLA-4 antibody to demonstrate clinical responses across 9 cold, treatment-resistant cancers; Phase II studies planned in melanoma, MSS-colorectal, and pancreatic cancers ? AGEN1571, a novel program targeting tumor-associated macrophages, is entering clinical dev |
|
| February 17, 2022 |
AGEN / Agenus Inc / GILEAD SCIENCES INC Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2. (Amendment No. 1)* Agenus Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 00847G705 (CUSIP Number) December 31, 2021 (Date of Ev |
|
| February 14, 2022 |
AGEN / Agenus Inc / RTW INVESTMENTS, LP - AGENUS INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Agenus Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 00847G705 (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which t |
|
| February 11, 2022 |
AGEN / Agenus Inc / FEINBERG LARRY N - SCHEDULE 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 2 (EXIT FILING) Under the Securities Exchange Act of 1934 AGENUS INC. (Name of Issuer) Common Stock (Title of Class of Securities) 00847G705 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| February 11, 2022 |
AGEN / Agenus Inc / INCYTE CORP - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Agenus Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 00847G705 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan |
|
| February 10, 2022 |
AGEN / Agenus Inc / GILEAD SCIENCES INC Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 1)* Agenus Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 00847G705 (CUSIP Number) December 31, 2021 (Date of Ev |
|
| February 9, 2022 |
AGEN / Agenus Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Agenus Inc. Title of Class of Securities: Common Stock CUSIP Number: 00847G705 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13 |
|
| January 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 31, 2021 Date of Report (Date of earliest event reported) AGENUS INC. (Exact name of registrant as specified in its charter) DELAWARE 000-29089 06-1562417 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| November 12, 2021 |
As filed with the Securities and Exchange Commission on November 12, 2021 Table of Contents As filed with the Securities and Exchange Commission on November 12, 2021 Registration No. |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29089 Agenus Inc. (exa |
|
| November 9, 2021 |
Agenus Corporate Update and Third Quarter 2021 Financial Report EXHIBIT 99.1 Agenus Corporate Update and Third Quarter 2021 Financial Report Clinical results presented at SITC show that AGEN1181, as a monotherapy and in combination with balstilimab, shows durable responses in 9 cancer types, including patients whose cancers have recurred following PD-1 therapy Agenus will commence Phase 2/3 trials of AGEN1181 and balstilimab in colorectal and several gynecolog |
|
| November 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 9, 2021 Date of Report (Date of earliest event reported) AGENUS INC. (Exact name of registrant as specified in its charter) Delaware 000-29089 06-1562417 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| October 28, 2021 |
IMRA / Imara Inc / AGENUS INC - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 MINK THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 603693102 (CUSIP Number) Garo H. Armen, Ph.D. Chairman and CEO Agenus Inc. 3 Forbes Road Lexington, MA 02421 (781) 674-4400 Copy to: Ropes & Gray LLP Prudential Tower 800 Boylston Street B |
|
| October 28, 2021 |
Exhibit 99.1 Execution Version MiNK Therapeutics, Inc. (a Delaware corporation) 3,333,334 Shares of Common Stock UNDERWRITING AGREEMENT Dated: October 14, 2021 MiNK Therapeutics, Inc. (a Delaware corporation) 3,333,334 Shares of Common Stock UNDERWRITING AGREEMENT October 14, 2021 Evercore Group L.L.C. William Blair & Company, L.L.C. as Representatives of the several Underwriters c/o Evercore Grou |
|
| October 22, 2021 |
Agenus Provides Update on Balstilimab Development Exhibit 99.1 Agenus Provides Update on Balstilimab Development ? Company voluntarily withdraws BLA at FDA?s recommendation following full approval of pembrolizumab, which came four months earlier than FDA goal date ? Balstilimab achieved trial endpoints with 20% response rates in PD-L1 positive patients, versus 14% reported in pembrolizumab?s label; Agenus successfully completed 3 FDA pre-approval |
|
| October 22, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 22, 2021 AGENUS INC. (Exact name of registrant as specified in its charter) DELAWARE 000-29089 06-1562417 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 9, 2021 |
Exhibit 10.2 AMENDMENT NO. 1 TO ROYALTY Purchase AGREEMENT This Amendment No. 1 to Royalty Purchase Agreement (this ?Amendment?) is made and entered into as of June 22, 2021 by and among Antigenics LLC, a Delaware limited liability company (the ?Seller?) and the entities set forth on Schedule 1 to the (as defined below) Agreement in the proportions set forth thereon (collectively, the ?Buyer?). Ca |
|
| August 9, 2021 |
Agenus Corporate Update and Second Quarter 2021 Financial Report EXHIBIT 99.1 Agenus Corporate Update and Second Quarter 2021 Financial Report $200M received from BMS for anti-TIGIT bispecific antibody collaboration FDA cleared IND for AGEN1777 clinical enrollment AGEN1181 rapidly advancing in the clinic; data to be presented in 2H 2021 Cell therapy subsidiary MiNK Therapeutics filed confidential S-1 for planned IPO FDA accepted balstilimab BLA for Priority Rev |
|
| August 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 9, 2021 Date of Report (Date of earliest event reported) Agenus Inc. (Exact name of registrant as specified in its charter) Delaware 000-29089 06-1562417 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| August 9, 2021 |
Exhibit 10.1 Execution Version LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT DATED AS OF MAY 17, 2021 BY AND BETWEEN AGENUS INC. AND BRISTOL-MYERS SQUIBB COMPANY [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. Exhibit 10.1 Table of Contents ARTICLE 1 DEFINITIO |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29089 Agenus Inc. (exact na |
|
| July 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2021 AGENUS INC. (Exact name of registrant as specified in its charter) Delaware 000-29089 06-1562417 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 16, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2021 AGENUS INC. (Exact name of registrant as specified in its charter) Delaware 000-29089 06-1562417 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 18, 2021 |
Exhibit 99.1 Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus? Anti-TIGIT Bispecific Antibody Program Agenus to receive a $200 million upfront payment and up to $1.36 billion in milestone payments NEW YORK & LEXINGTON, Mass.? May 18, 2021? Bristol-Myers Squibb Company (NYSE: BMY) and Agenus Inc. (NASDAQ: AGEN) today announced that they have entered into a definitive agr |
|
| May 18, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2021 AGENUS INC. (Exact name of registrant as specified in its charter) Delaware 000-29089 06-1562417 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| May 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| May 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29089 Agenus Inc. (exact n |
|
| May 6, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 6, 2021 Date of Report (Date of earliest event reported) Agenus Inc. (Exact name of registrant as specified in its charter) Delaware 000-29089 06-1562417 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| May 6, 2021 |
Agenus Corporate Update and First Quarter 2021 Financial Report EXHIBIT 99.1 Agenus Corporate Update and First Quarter 2021 Financial Report Balstilimab BLA submitted to FDA for recurrent/metastatic cervical cancer Balstilimab and AGEN2373 data to be presented at ASCO iNKT cell therapy Phase 1 initiated in cancer LEXINGTON, Mass., May 06, 2021 (GLOBE NEWSWIRE) - Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint ant |
|
| April 30, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2021 AGENUS INC. (Exact name of registrant as specified in its charter) Delaware 000-29089 06-1562417 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| March 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29089 Agenus Inc. (exact name o |
|
| March 16, 2021 |
Subsidiaries of Agenus Inc. Filed herewith. EXHIBIT 21.1 SUBSIDIARIES OF AGENUS INC. Antigenics LLC., a Delaware limited liability company and a wholly-owned subsidiary of Agenus Inc. Agenus Royalty Fund, LLC, a Delaware limited liability company and a wholly-owned subsidiary of Agenus Inc. Agenus Switzerland Inc., a joint stock company organized under the laws of Switzerland formerly known as 4-Antibody AG, and a wholly-owned subsidiary of |
|
| March 15, 2021 |
Agenus Corporate Update and Fourth Quarter & Full Year 2020 Financial Report EXHIBIT 99.1 Agenus Corporate Update and Fourth Quarter & Full Year 2020 Financial Report Completion of balstilimab BLA filing on target for 1H 2021 New clinical data for AGEN1181 to be presented at AACR TIGIT bispecific AGEN1777 IND to be filed in 2Q 2021 iNKT cell therapy cancer trials to commence in 1H 2021 LEXINGTON, Mass., March 15, 2021 (GLOBE NEWSWIRE) - Agenus Inc. (NASDAQ: AGEN), an immun |
|
| March 15, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 15, 2021 Date of Report (Date of earliest event reported) Agenus Inc. (Exact name of registrant as specified in its charter) Delaware 000-29089 06-1562417 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 1 Under the Securities Exchange Act of 1934 AGENUS INC. (Name of Issuer) Common Stock (Title of Class of Securities) 00847G705 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Agenus Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 00847G705 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 12, 2021 |
Joint Filing Statement Pursuant to Rule 13D-1(K)(1) Exhibit 1 Joint Filing Statement Pursuant to Rule 13D-1(K)(1) The undersigned hereby consent and agree to the joint filing of Schedule 13G Amendment No. |
|
| February 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Agenus Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 00847G705 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan |
|
| February 10, 2021 |
SC 13G 1 tv0147-agenusinc.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Agenus Inc. Title of Class of Securities: Common Stock CUSIP Number: 00847G705 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Sched |
|
| January 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2021 AGENUS INC. (Exact name of registrant as specified in its charter) Delaware 000-29089 06-1562417 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| November 25, 2020 |
EX-10.1 2 d48128dex101.htm EX-10.1 Exhibit 10.1 OFFICE LEASE BAY CENTER OFFICES Emeryville, California BAY CENTER INVESTOR LLC, as LANDLORD, and AGENUS INC., as TENANT TABLE OF CONTENTS Page 1. Definitions 1 2. Tenant’s and Landlord’s Rights 6 3. Term; Condition and Acceptance of Premises 7 4. Rent 11 5. Calculation and Payments of Escalation Rent 12 6. Impositions Payable by Tenant 14 7. Use of P |
|
| November 25, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 25, 2020 AGENUS INC. (Exact name of registrant as specified in its charter) Delaware 000-29089 06-1562417 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| November 9, 2020 |
Exhibit 10.1 Executive Employment AGREEMENT THIS Executive Employment AGREEMENT (this “Agreement”) is made and entered into in Lexington, MA, by and between Agenus Inc. (the “Company”), a Delaware corporation with a principal place of business at 3 Forbes Rd. Lexington, MA 02421, and Evan D. Kearns (the “Executive”), effective as of this 6th day of November, 2020 (the “Effective Date”). Words or p |
|
| November 9, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29089 Agenus Inc. (exa |
|
| October 29, 2020 |
Agenus R&D Update & Third Quarter Financial Report EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Agenus R&D Update & Third Quarter Financial Report Balstilimab rolling BLA filing and FDA review underway COVID-19 trial open with patients in screening for iNKT Cell Therapy New data and clinical responses with AGEN1181 to be presented at SITC on NOV11 LEXINGTON, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) - Agenus Inc. (NASDAQ: AGEN), an immuno-oncology |
|
| October 29, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 29, 2020 Date of Report (Date of earliest event reported) Agenus Inc. (Exact name of registrant as specified in its charter) Delaware 000-29089 06-1562417 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| October 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 8, 2020 AGENUS INC. (Exact name of registrant as specified in its charter) Delaware 000-29089 06-1562417 (State or other jurisdiction of incorporation) (Commission File Number |
|
| October 13, 2020 |
Susan Hirsch Joins Agenus’ Board of Directors EX-99.1 2 d75332dex991.htm EX-99.1 Exhibit 99.1 Susan Hirsch Joins Agenus’ Board of Directors LEXINGTON, Mass., October 13, 2020 /GLOBE NEWSWIRE/ — Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced the election of Ms. Susan |
|
| August 31, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 27, 2020 AGENUS INC. (Exact name of registrant as specified in its charter) Delaware 000-29089 06-1562417 (State or other jurisdiction of incorporation) (Commission File Number |
|
| August 31, 2020 |
Paul Clark Joins Agenus Board of Directors EX-99.1 Exhibit 99.1 Paul Clark Joins Agenus Board of Directors LEXINGTON, Mass., August 31, 2020 /PRNewswire/ — Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced the election of Mr. Paul Clark to Agenus’ Board of Directors. |
|
| August 10, 2020 |
EX-99.1 Exhibit 99.1 Agenus Provides R&D Update & Second Quarter Financial Report • Dr. Chuck Drake & Dr. Bree Wilky to discuss AGEN1181 & zalifrelimab - new responses • AGEN2373 achieves durable SDs in early Ph1; balstilimab combos to start • Zalifrelimab achieves responses in PD-1 failures (1CR, 3PRs); Ph2 expansion underway • Next-gen CTLA-4, PD-1 & iNKT activating therapy shows curative potent |
|
| August 10, 2020 |
EX-99.3 August 2020 This version of the presentation includes corrections to an error in the original presentation contained on slide 10. Exhibit 99.3 Forward-Looking Statements This presentation contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding clinical development and regulatory plans and timeli |
|
| August 10, 2020 |
EX-10.1 3 agen-ex101149.htm EX-10.1 Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [*], HAS BEEN OMITTED BECAUSE Agenus INC., HAS DETERMINED such INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO AGENUS INC., IF PUBLICLY DISCLOSED. LICENSE AND COLLABORATION AGREEMENT This LICENSE AND COLLABORATION AGREEMENT (this “Agreement”) is mad |
|
| August 10, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 6, 2020 Date of Report (Date of earliest event reported) AGENUS INC. (Exact name of registrant as specified in its charter) DELAWARE 000-29089 06-1562417 (State or other jurisdiction (Commission (IRS Employer of incorporat |
|
| August 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29089 Agenus Inc. (exact na |
|
| August 10, 2020 |
Agenus (NASDAQ: AGEN) Q2 2020 Earnings Conference Call EX-99.2 3 d44878dex992.htm EX-99.2 Exhibit 99.2 Agenus (NASDAQ: AGEN) Q2 2020 Earnings Conference Call August 6, 2019 8:30 AM ET Agenus (NASDAQ: AGEN) Q2 2020 Earnings Conference Call Officers and Speakers Garo Armen, Ph.D. - Chairman and Chief Executive Officer Jennifer S. Buell, Ph.D. - Chief Operating Officer Dhan Chand, PhD - Head of Drug Discovery Julie Desander - Vice President, Business Dev |
|
| August 10, 2020 |
Exhibit 4.1 Execution Version stock PURCHASE AGREEMENT This Stock Purchase Agreement (this “Agreement”) is dated as of June 20, 2020, by and between Agenus Inc., a Delaware corporation (the “Company”), Betta Investment (Hong Kong) Limited (貝達投資(香港)有限公司), a limited liability company established under the laws of Hong Kong (“Purchaser”), and Betta Pharmaceuticals Co., Ltd. (贝达药业股份有限公司), a limited li |
|
| July 31, 2020 |
AGEN / Agenus Inc. / FEINBERG LARRY N - SC 13G Passive Investment SC 13G 1 tm2026139d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 AGENUS INC. (Name of Issuer) Common Stock (Title of Class of Securities) 00847G705 (CUSIP Number) July 22, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| July 31, 2020 |
SCHEDULE 13G JOINT FILING AGREEMENT Exhibit 99.1 SCHEDULE 13G JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (as so amended, the “Schedule 13G”) with respect to the common stock of Agenus Inc. is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 13d-1(k) under the Securities Exchange Ac |
|
| July 28, 2020 |
Agenus Receives $35M In Immuno-Oncology Transaction with Betta Pharmaceuticals EX-99.1 2 d44294dex991.htm EX-99.1 Exhibit 99.1 Agenus Receives $35M In Immuno-Oncology Transaction with Betta Pharmaceuticals Lexington, Mass., July 28, 2020 – Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with an extensive pipeline of agents designed to activate immune response to cancers, today announced the closing of a $20 million equity investment, at $4.03 per share, by Betta |
|
| July 28, 2020 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2020 AGENUS INC. (Exact name of registrant as specified in its charter) Delaware 000-29089 06-1562417 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| July 22, 2020 |
S-3ASR Table of Contents As filed with the Securities and Exchange Commission on July 22, 2020 Registration No. |
|
| July 22, 2020 |
EX-4.1 3 d74660dex41.htm EX-4.1 Exhibit 4.1 AGENUS INC. and [ ], as Trustee INDENTURE Dated as of [ ], [ ] TABLE OF CONTENTS ARTICLE 1. DEFINITIONS AND INCORPORATION BY REFERENCE 6 1.1. DEFINITIONS. 6 1.2. OTHER DEFINITIONS. 10 1.3. INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT. 12 1.4. RULES OF CONSTRUCTION. 12 ARTICLE 2. THE SECURITIES 12 2.1. ISSUABLE IN SERIES. 12 2.2. ESTABLISHMENT OF TER |
|
| July 22, 2020 |
EX-1.2 Exhibit 1.2 AGENUS INC. Common Stock (par value $0.01 per share) At Market Issuance Sales Agreement July 22, 2020 B. Riley FBR, Inc. 299 Park Avenue, 21st Floor New York, NY 10017 Ladies and Gentlemen: Agenus Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with B. Riley FBR, Inc. (the “Agent”), as follows: 1. Issuance and Sale of Shares. The Company a |
|
| June 22, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2020 AGENUS INC. (Exact name of registrant as specified in its charter) Delaware 000-29089 06-1562417 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| June 22, 2020 |
EX-99.1 Exhibit 99.1 Agenus and Betta Pharmaceuticals Enter Into a License Agreement for Balstilimab and Zalifrelimab in Greater China • Agenus to receive $35M upfront with $100M in milestones plus royalties • Betta receives exclusive license of balstilimab (anti-PD-1) and zalifrelimab (anti-CTLA-4) in Greater China LEXINGTON, Mass., June 22, 2020 /PRNewswire/ — Agenus Inc. (NASDAQ: AGEN), an immu |
|
| June 22, 2020 |
Submission of Matters to a Vote of Security Holders 8-K 1 d920641d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2020 AGENUS INC. (Exact name of registrant as specified in its charter) Delaware 000-29089 06-1562417 (State or other jurisdiction of incorporation) |
|
| May 11, 2020 |
Exhibit 10.1 CONSULTING AGREEMENT This Consulting Agreement (the “Agreement”), effective as of January 1, 2020 (the “Effective Date”), is made between Agenus Inc., a Delaware corporation, having an address at 149 Fifth Avenue, Suite 500, New York, NY 10010 (“Agenus”), and Brian Corvese, an individual having an address at PO Box 49, Westport, CT 06881 (the “Consultant”) (each a “Party” and collecti |
|
| May 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29089 Agenus Inc. (exact n |
|
| May 7, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 7, 2020 Date of Report (Date of earliest event reported) AGENUS INC. (Exact name of registrant as specified in its charter) DELAWARE 000-29089 06-1562417 (State or other jurisdiction (Commission (IRS Employer of incorporation) Fi |
|
| May 7, 2020 |
Agenus First Quarter Results and Update EX-99.1 2 d924651dex991.htm EX-99.1 Exhibit 99.1 Agenus First Quarter Results and Update - AGEN1181 (nextgen CTLA-4) +/- balstilimab (anti-PD-1) shows benefit in 70% of patients in Phase 1 - Balstilimab + Zalifrelimab (anti-CTLA-4) achieve 26% response rates in a cohort of 55 patients with advanced cervical cancer - Two INDs filed for AgenTus cell therapy (Allogeneic iNKTs) for cancer & COVID-19 - |
|
| May 7, 2020 |
May 2020 Exhibit 99.2 Forward-Looking Statements This presentation contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding Agenus and AgenTus' clinical development and regulatory plans and timelines, expected timing for clinical trials and releasing clinical data, anticipated milestones from partnership |
|
| April 28, 2020 |
DEF 14A 1 d860799ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Com |
|
| March 30, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2020 AGENUS INC. (Exact name of registrant as specified in its charter) Delaware 000-29089 06-1562417 (State or other jurisdiction of incorporation) (Commission File Num |
|
| March 20, 2020 |
AGEN / Agenus Inc. / Cormorant Asset Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Agenus Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 00847G705 (CUSIP Number) March 10, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is fil |
|
| March 20, 2020 |
EX-99.1 2 schedule991.htm Exhibit 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of March 20, 2020, is by and among Cormorant Global Healthcare Master Fund, LP, Cormorant Global Healthcare GP, LLC, Cormorant Asset Management, LP and Bihua Chen (collectively, the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commission a stat |
|
| March 16, 2020 |
Exhibit 10.10.1 Name: [] Number of Shares of Stock subject to the Stock Option: [] Exercise Price Per Share: $[] Date of Grant: [] Vesting: [] Agenus Inc. 2019 Equity Incentive Plan Incentive Stock Option Stock Option Award Agreement This agreement (this “Agreement”) evidences a stock option granted by Agenus Inc. (the “Company”) to the individual named above (the “Participant”), pursuant to and s |
|
| March 16, 2020 |
Exhibit 10.10.2 Name: [] Number of Shares of Stock subject to the Stock Option: [] Exercise Price Per Share: $[] Date of Grant: [] Vesting: [] Agenus Inc. 2019 Equity Incentive Plan Non-Qualified Stock Option Stock Option Award Agreement This agreement (this “Agreement”) evidences a stock option granted by Agenus Inc. (the “Company”) to the individual named above (the “Participant”), pursuant to a |
|
| March 16, 2020 |
Exhibit 4.7 AMENDMENT TO NOTES AND WARRANTS And Sale of New Warrants This Amendment to Notes and Warrants and Sale of New Warrants (this “Amendment”) is entered into this 18th day of February 2020 by and between (a) Agenus Inc., a Delaware corporation, having an address at 3 Forbes Road, Lexington, MA 02421 (the “Borrower”), and (b) Mark Berg and Nicole Berg, Nicky V LLC and MSB Research Inc. (col |
|
| March 16, 2020 |
Subsidiaries of Agenus Inc. Filed herewith. EXHIBIT 21.1 SUBSIDIARIES OF AGENUS INC. Antigenics LLC., a Delaware limited liability company and a wholly-owned subsidiary of Agenus Inc. Aronex Pharmaceuticals, Inc., a Delaware corporation and a wholly-owned subsidiary of Agenus Inc. Antigenics Therapeutics Limited, a company organized under the laws of Ireland and a wholly-owned subsidiary of Agenus Inc. Agenus Royalty Fund, LLC, a Delaware l |
|
| March 16, 2020 |
Exhibit 10.10.3 Name: [] Number of Restricted Stock Units: [] Date of Grant: [] Vesting: [] Agenus Inc. 2019 Equity Incentive Plan Restricted Stock Unit Award Agreement This agreement (this “Agreement”) evidences an award (the “Award”) of restricted stock units granted by Agenus Inc. (the “Company”) to the individual named above (the “Participant”), pursuant to and subject to the terms of the Agen |
|
| March 16, 2020 |
AGEN / Agenus Inc. 10-K - Annual Report - 10-K 10-K 1 agen-10k20191231.htm 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| March 16, 2020 |
Exhibit 4.8 WARRANT THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED OR ASSIGNED UNLESS (I) A REGISTRATION STATEMENT COVERING SUCH SHARES IS EFFECTIVE UN |
|
| March 16, 2020 |
Exhibit 4.12 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following summary description of the Common Stock (as defined below) of Agenus Inc. (the “Company”) is based on the provisions of the Company’s Amended and Restated Certificate of Incorporation (as amended, the “Charter”), the Company’s Fifth Amended and Restated By- |
|
| March 12, 2020 |
Agenus Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update Exhibit 99.1 Agenus Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update - AGEN1181 +/- balstilimab (anti-PD-1) reveals a complete response and new partial responses in phase 1 clinical trial - Balstilimab & zalifrelimab (anti-CTLA-4) demonstrate 26.5% response rates in an all-comer (non-biomarker selected) population with advanced cervical cancer - FDA grants |
|
| March 12, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 12, 2020 Date of Report (Date of earliest event reported) AGENUS INC. (Exact name of registrant as specified in its charter) DELAWARE 000-29089 06-1562417 (State or other jurisdiction (Commission (IRS Employer of incorporation) |
|
| March 12, 2020 |
Exhibit 99.2 Earnings Call: 4Q and Full Year 2019 Earnings March 12, 2020 This presentation contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding Agenus and AgenTus' clinical development and regulatory plans and timelines, expected timing for clinical trials and releasing clinical data, expected clini |
|
| February 24, 2020 |
8-K 1 d889322d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2020 AGENUS INC. (Exact name of registrant as specified in its charter) Delaware 000-29089 06-1562417 (State or other jurisdiction of incorporati |
